ClinicalTrials.gg
CompletedNCT01146951Updated Jan 24, 2018Results posted

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

A Phase 3 interventional study of Rufinamide (E2080) and Placebo in Lennox-Gastaut Syndrome, sponsored by Eisai Limited. Completed at 23 sites in Japan. Open to participants aged 4 Years to 30 Years. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
4 Years to 30 Years
Sex
All
01

Study summary

To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.

02

Conditions studied

  • Lennox-Gastaut Syndrome

Keywords

  • Epilepsy
  • Seizures
03

In context

Lennox Gastaut Syndrome

68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.

This study's enrollment of 66 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.

Browse Lennox Gastaut Syndrome studies →

Lead sponsor

Eisai Limited is the lead sponsor of 48 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are diagnosed as Lennox-Gastaut syndrome with tonic/atonic seizures and atypical absence seizures (A history of atypical absence seizures will also be incorporated).
  2. Participants who had a slow spike-and-wave pattern in an electroencephalogram within 6 months prior to the enrollment for the Observation Period.
  3. Participants who had at least a total of 90 seizures in the 28 days prior to the enrollment for the Observation Period.
  4. Participants who have been on 1 - 3 anti-epileptic drugs from 28 days prior to the enrollment for the Observation Period and have not changed the type of the anti-epileptic drugs.
  5. Participants who have not changed the type nor the dose or administration of the anti-epileptic drugs they are taking in the Observation Period.

Exclusion criteria

Exclusion criteria;

  1. Participants who had a history of generalized tonic-clonic status epilepticus within baseline.
  2. Participants who received drug therapy at least 4 times to be rescued from status epilepticus within baseline.
  3. Participants who had a history of hypoxia which needed emergency resuscitation within 12 months prior to the Treatment Period.
  4. Participants who were on a ketogenic diet or have received adrenocorticotropic hormone (ACTH) therapy or Vitamin B6 therapy within 6 months prior to the Treatment Period.
  5. Participants who had a history of suicide attempt within the 1 year prior to the Treatment Period.
  6. Participants who had a history of or has an allergy to triazole compound.
  7. Participants who have abnormalities at baseline.
  8. Participants who are pregnant, who may be pregnant, who are lactating or who wish to be pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Rufinamide (E2080)

    Drug: Rufinamide (E2080)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period. Target maintenance dose: 15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)

    Also known as: E2080

  • DrugPlacebo

    Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.

06

What researchers measure

Primary outcomes

  1. Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)

    The sum of the frequencies of tonic seizures and atonic seizures was defined as the "tonic-atonic seizure frequency" and the percent change in tonic-atonic seizure frequency per 28 days was assessed. The percent change in tonic-atonic seizure frequency was calculated using the tonic-atonic seizure frequency per 28 days of the Observation Period as the baseline and the tonic-atonic seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in tonic - atonic seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. The frequency of epileptic seizures was recorded in the seizure diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner, and continued these practices throughout the study period.

    Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)

Secondary outcomes

  1. Number of Participants Achieving a 50% Reduction in Tonic-atonic Seizure Frequency

    50% Responder Rate in Tonic-Atonic Seizure Frequency was presented as the number of participants who achieved a 50% reduction in tonic-atonic seizure frequency.

    Time frame: 12 weeks

  2. Percent Change in Total Seizure Frequency (Per 28 Days)

    Percent change in the total seizure frequency (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\].

    Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)

  3. Percentage Change in the Frequency of Seizures Other Than Tonic-atonic Seizures (Per 28 Days)

    Percent change in the frequency of seizures other than tonic-atonic seizures (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. Seizures analyzed other than tonic-atonic seizures included: Partial seizure freq. (frequency), Absence seizure, Atyp. (atypical) absence seizure, Myoclonic seizure, Clonic seizure, Tonic seizure, Tonic-clonic seizure, Atonic seizure, \& Uncla. (unclassified) epileptic seizure. The frequency of epileptic seizures was recorded in the diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner.

    Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)

  4. Clinical Global Impression of Change (CGIC)

    CGIC in participants with Lennox-Gastaut Syndrome (LGS) relative to placebo was presented as number of participants in each category at the final assessment (last observation carried forward \[LOCF\]) \& at Week 12 of the Treatment Period. The investigator assessed the CGIC by comparing the participants' condition during the 4 weeks immediately before the completion (or discontinuation \[d/c\]) of the Treatment Period to his/her condition during the 4-week Observation Period (for participants who d/c'd the study during the Treatment Period, the CGIC was assessed by comparing the participant's condition from the start to discontinuation of the study treatment to his/her condition during the 4-week Observation Period). The CGIC was assessed according to the following 7-grade scale based on the frequency \& severity of seizures, AEs, and overall conditions of daily life. Markedly improved, Improved, Slightly improved, Unchanged, Slightly worsened, Worsened, Markedly worsened.

    Time frame: Up to Week 12 of the treatment period

07

Results

Posted Nov 21, 2013

Participant flow

Participant flow — Overall Study
MilestoneRufinamide (E2080)Placebo
Started2930
Completed2529
Not completed41
Withdrew: Adverse event41

Outcome measures

PrimaryPercent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)

The sum of the frequencies of tonic seizures and atonic seizures was defined as the "tonic-atonic seizure frequency" and the percent change in tonic-atonic seizure frequency per 28 days was assessed. The percent change in tonic-atonic seizure frequency was calculated using the tonic-atonic seizure frequency per 28 days of the Observation Period as the baseline and the tonic-atonic seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in tonic - atonic seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. The frequency of epileptic seizures was recorded in the seizure diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner, and continued these practices throughout the study period.

Time frame:
Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Reported as:
Median · Percent Change
Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)
Percent ChangeRufinamide (E2080)Placebo
Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)-24.20 (-93.5 to 27.2)-3.25 (-81.6 to 151.9)
Statistical analysis
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.003 · Hodges-lehmann: -26.65 · 90% CI -40.30 to -11.80
SecondaryNumber of Participants Achieving a 50% Reduction in Tonic-atonic Seizure Frequency

50% Responder Rate in Tonic-Atonic Seizure Frequency was presented as the number of participants who achieved a 50% reduction in tonic-atonic seizure frequency.

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants Achieving a 50% Reduction in Tonic-atonic Seizure Frequency
ParticipantsRufinamide (E2080)Placebo
Yes (50% Reduction Achieved)72
No2128
Statistical analysis
  • Rufinamide (E2080) vs Placebo · Fisher's exact test · p = 0.074
SecondaryPercent Change in Total Seizure Frequency (Per 28 Days)

Percent change in the total seizure frequency (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\].

Time frame:
Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Reported as:
Median · Percent Change
Percent Change in Total Seizure Frequency (Per 28 Days)
Percent ChangeRufinamide (E2080)Placebo
Percent Change in Total Seizure Frequency (Per 28 Days)-32.90 (-87.3 to 15.4)-3.05 (-52.2 to 133.0)
Statistical analysis
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 · Hodges-lehmann method: -33.30 · 90% CI -47.10 to -17.00
SecondaryPercentage Change in the Frequency of Seizures Other Than Tonic-atonic Seizures (Per 28 Days)

Percent change in the frequency of seizures other than tonic-atonic seizures (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. Seizures analyzed other than tonic-atonic seizures included: Partial seizure freq. (frequency), Absence seizure, Atyp. (atypical) absence seizure, Myoclonic seizure, Clonic seizure, Tonic seizure, Tonic-clonic seizure, Atonic seizure, \& Uncla. (unclassified) epileptic seizure. The frequency of epileptic seizures was recorded in the diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner.

Time frame:
Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Reported as:
Median · Percent change
Percentage Change in the Frequency of Seizures Other Than Tonic-atonic Seizures (Per 28 Days)
Percent changeRufinamide (E2080)Placebo
Partial Seizure Freq. % Change (n=4,6)-52.20 (-96.2 to -26.3)4.5 (-28.2 to 35.9)
Absence Seizure Freq. % Change (n=1,0)3.40 (3.4 to 3.4)NA (NA to NA)
Atyp. Absence Seizure Freq. % Change (n=12,19)-59.00 (-100.0 to 107.1)-21.10 (-83.2 to 253.5)
Myoclonic Seizure Freq. % Change (n=10,10)-52.35 (-100.0 to 53.3)6.60 (-46.1 to 270.0)
Clonic Seizure Freq. % Change (n=1,0)-81.20 (-81.2 to -81.2)NA (NA to NA)
Tonic Seizure Freq. % Change (n=28,28)-24.20 (-92.6 to 42.8)-3.60 (-83.8 to 274.8)
Tonic-clonic Seizure Freq. % Change (n=2,10)-57.35 (-100.0 to -14.7)2.35 (-75.8 to 450.0)
Atonic Seizure Freq. % Change (n=10,12)-63.10 (-100.0 to 68.8)-6.10 (-100.0 to 2195.7)
Uncla. Epileptic Seizure Freq. % Change (n=1,0)-88.70 (-88.7 to -88.7)NA (NA to NA)
Statistical analysis
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.025 · Hodges-lehmann method: -57.15 · 90% CI -104.50 to -17.30
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.128 · Hodges-lehmann method: -28.65 · 90% CI -72.00 to 0.90
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.021 · Hodges-lehmann method: -54.35 · 90% CI -126.60 to -15.40
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.031 · Hodges-lehmann method: -23.20 · 90% CI -40.70 to -5.60
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.107 · Hodges-lehmann method: -71.40 · 90% CI -464.70 to 30.50
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.221 · Hodges-lehmann method: -52.10 · 90% CI -89.10 to 10.80
SecondaryClinical Global Impression of Change (CGIC)

CGIC in participants with Lennox-Gastaut Syndrome (LGS) relative to placebo was presented as number of participants in each category at the final assessment (last observation carried forward \[LOCF\]) \& at Week 12 of the Treatment Period. The investigator assessed the CGIC by comparing the participants' condition during the 4 weeks immediately before the completion (or discontinuation \[d/c\]) of the Treatment Period to his/her condition during the 4-week Observation Period (for participants who d/c'd the study during the Treatment Period, the CGIC was assessed by comparing the participant's condition from the start to discontinuation of the study treatment to his/her condition during the 4-week Observation Period). The CGIC was assessed according to the following 7-grade scale based on the frequency \& severity of seizures, AEs, and overall conditions of daily life. Markedly improved, Improved, Slightly improved, Unchanged, Slightly worsened, Worsened, Markedly worsened.

Time frame:
Up to Week 12 of the treatment period
Reported as:
Number · participants
Clinical Global Impression of Change (CGIC)
participantsRufinamide (E2080)Placebo
Week 12: Markedly improved (n=25, 29)00
Week 12: Improved (n=25, 29)90
Week 12: Slightly Improved (n=25, 29)49
Week 12: Unchanged (n=25, 29)1018
Week 12: Slightly Worsened (n=25, 29)11
Week 12: Worsened (n=25, 29)11
Week 12: Markedly Worsened (n=25, 29)00
LOCF: Markedly Improved (n=28, 30)30
LOCF: Improved (n=28, 30)90
LOCF: Slightly Improved (n=28, 30)49
LOCF: Unchanged (n=28, 30)1019
LOCF: Slightly Worsened (n=28, 30)11
LOCF: Worsened (n=28, 30)11
LOCF: Markedly Worsened (n=28, 30)00
Statistical analysis
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.041
  • Rufinamide (E2080) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.007

Adverse events

Collected over From date of first dose until date of last dose of study treatment, up to approximately 1 year 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rufinamide (E2080)—1/29 (3.4%)27/29 (93.1%)
Placebo—1/30 (3.3%)21/30 (70%)
Most frequent serious events
Most frequent serious events
EventRufinamide (E2080)Placebo
Drug EruptionSkin and subcutaneous tissue disorders1/291/30
Most frequent other events
Showing 10 of 49
Most frequent other events
EventRufinamide (E2080)Placebo
NasopharyngitisInfections and infestations9/299/30
Status EpilepticusNervous system disorders8/295/30
Decreased AppetiteMetabolism and nutrition disorders6/292/30
SomnolenceNervous system disorders6/292/30
VomitingGastrointestinal disorders5/291/30
Upper Respiratory Tract InfectionInfections and infestations2/294/30
Dental CariesGastrointestinal disorders2/290/30
NauseaGastrointestinal disorders2/290/30
DehydrationMetabolism and nutrition disorders2/290/30
GastroenteritisInfections and infestations0/292/30

Baseline characteristics

One subject from the Rufinamide (E2080) group was excluded from the FAS because of the inappropriate diagnosis of the disease, dropping the total number from 29 to 28 participants.

Age, Continuous
Age, Continuous(years)Rufinamide (E2080)PlaceboTotal
Mean16.0 ± 7.113.9 ± 6.114.9 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Rufinamide (E2080)PlaceboTotal
Female111122
Male171936
08

Study locations

23 sites
  • Nagoya-shi, Aichi, Japan
  • Matsuyama-shi, Ehime, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Kobe-shi, Hyogo, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Goshi-shi, Kumamoto, Japan
  • Iwamuma-shi, Miyagi, Japan
  • Omura-shi, Nagasaki, Japan
  • Nara-shi, Nara, Japan
  • Niigata-shi, Niigata, Japan
  • Yufu-shi, Oita, Japan
  • Okayama-shi, Okayama, Japan
  • Neyagawa-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Moriya-shi, Shiga, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Kodaira-shi, Tokyo, Japan
  • Kokubunji-shi, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Toyoma-shi, Toyama, Japan
09

References and documents

Publications

  • Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021 Apr 7;4(4):CD003277. doi: 10.1002/14651858.CD003277.pub4. PubMed 33825230 ↗
  • Panebianco M, Prabhakar H, Marson AG. Rufinamide add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Nov 8;11(11):CD011772. doi: 10.1002/14651858.CD011772.pub3. PubMed 33179247 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2010
First posted
Jun 22, 2010
Start
Jun 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Nov 21, 2013
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01146951
Lead sponsor
Eisai Limited
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jun 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Nov 21, 2013
Last update
Jan 24, 2018

Study contacts

Hiroki Takano
study director · Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rufinamide

Start the discussion